|  | Functional declinea during rehabilitation unit stay | |||
---|---|---|---|---|---|
Study population n = 160 (%) | Yes n = 28 (%) | No n = 132 (%) | Crude OR [95% CI] †| P value ‡ | |
Baseline characteristics | |||||
 Age, years, median [Q1-Q3] | 84 [80–88] | 83 [81–87.5] | 84 [80–88] |  | 0.78 |
 Male sex | 44 (27.5) | 9 (32.1) | 35 (26.5) |  | 0.55 |
 Living alone | 110 (68.8) | 19 (67.9) | 91 (68.9) |  | 0.91 |
Place of residence | |||||
 Home or assisted-living facility | 155 (96.9) | 27 (96.4) | 128 (97.0) |  | 0.88 |
 Nursing home | 5 (3.1) | 1 (3.6) | 4 (3.0) |  |  |
Main acute diagnosis | Â | Â | Â | Â | 0.48 |
 Cardiovascular diseases | 36 (22.5) | 6 (21.4) | 30 (22.7) |  |  |
 Cerebrovascular diseases | 50 (31.2) | 12 (42.9) | 38 (28.8) |  |  |
 Orthopedic diseases (including fracture) | 35 (21.9) | 4 (14.3) | 31 (23.5) |  |  |
 Other diagnosisb | 39 (24.4) | 6 (21.4) | 33 (25.0) |  |  |
ADL at admission in rehabilitation unit, median [Q1-Q3] | 7 [4–10] | 5 [3–10] | 7.5 [4–10] | 0.91 [0.81–1.03] | 0.14 |
Comorbidities | |||||
 Global CIRS-G, median [Q1-Q3], OR/1-point increase (n = 164) | 11 [8–13] | 12.5 [10–15.5] | 10 [8–12] | 1.15 [1.03–1.28] | 0.01 |
 CIRS-G Index, median [Q1-Q3], OR/1-point increase | 4.0 [3.5–5.5] | 6 [4–6] | 4 [3–5] | 1.46 [1.14–1.86] | 0.003 |
Number of patients with CIRS-G score ≥ 2 in each category, n (%) | |||||
 Cardiovascular/respiratory system | |||||
  Heart disease | 101 (63.1) | 20 (71.4) | 81 (61.4) |  | 0.32 |
  Hypertension | 116 (72.5) | 19 (66.9) | 97 (73.5) |  | 0.55 |
  Vascular/hematological diseases | 44 (27.5) | 9 (32.1) | 35 (26.5) |  | 0.55 |
  Respiratory diseases | 34 (21.3) | 11 (39.3) | 23 (17.4) | 3.07 [1.27–7.41] | 0.01 |
  Eye, ear, nose and larynx diseases | 36 (22.5) | 6 (21.4) | 30 (22.7) |  | 0.88 |
 Gastrointestinal system | |||||
  Upper gastrointestinal diseases | 12 (7.5) | 3 (10.7) | 9 (6.8) |  | 0.48 |
  Lower gastrointestinal diseases | 13 (8.1) | 3 (10.7) | 10 (7.6) |  | 0.58 |
  Hepatic diseases | 1 (0.6) | 0 (0) | 1 (0.8) |  | – |
 Genitourinary system | |||||
  Renal diseases | 56 (35) | 14 (50) | 42 (31.8) | 2.14 [0.94–4.90] | 0.07 |
  Other urogenital diseases | 33 (20.6) | 8 (28.6) | 25 (18.9) | 1.71 [0.68–4.33] | 0.26 |
 Musculoskeletal/intergumentary system | |||||
  Muscle, bone, and skin diseases | 80 (50.0) | 16 (57.1) | 64 (48.5) |  | 0.41 |
 Neuropsychiatric system | |||||
  Neurological diseases | 42 (26.3) | 10 (35.7) | 32 (24.2) |  | 0.21 |
  Psychiatric diseases | 120 (75.0) | 25 (89.3) | 95 (72.0) | 3.25 [0.92–11.40] | 0.06 |
 General system | |||||
  Endocrine and metabolic diseases | 44 (27.5) | 10 (35.7) | 34 (25.8) |  | 0.29 |
  MMSE, median [Q1-Q3], OR/1-point decrease | 22 [17–26] | 18 [15–25] | 23 [18–27] | 1.10 [1.02–1.18] | 0.02 |
  MMSE < 24 | 87 (56.5) | 19 (70.4) | 68 (53.5) | 2.06 [0.84–5.05] | 0.11 |
  Albumin level < 35 g/L | 86 (53.5) | 21 (75) | 65 (49.2) | 3.09 [1.23–7.77] | 0.02 |
  CRP level, mg/L, median [Q1-Q3] | 6 [2.5–13] | 8 [2.5–17.5] | 5 [2.5–12.5] |  | 0.59 |
  Creatinine clearance Cockroft, ml/min, median [Q1-Q3], OR/1-point decrease (n = 164) | 41.5 [32.6–54.1] | 50.2 [30.5–55.8] | 40.4 [32.7–53.3] |  | 0.57 |
Hospital-acquired infection (HAI) | |||||
 Acquired infection during rehabilitation period c | 48 (30.0) | 12 (42.9) | 36 (27.3) | 2.00 [0.86–4.64] | 0.11 |
 Pulmonary HAI | 23 (14.4) | 8 (28.6) | 15 (11.4) | 3.12 [1.17–8.32] | 0.02 |
 Acquired urinary infection | 23 (14.4) | 5 (17.9) | 18 (13.6) |  | 0.56 |
 Other acquired infections | 5 (3.1) | 0 (0) | 5 (3.8) |  | – |